Drugs / Albumin paclitaxel
Albumin paclitaxel
Trials 51
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05344742 | Apr 2022 → Mar 2024 | neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04282070 | Mar 2020 → Apr 2022 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05777707 | Oct 2020 → Dec 2023 | carcinoma of esophagus | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT07244978 | Jun 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07045311 | Sep 2025 → Mar 2028 expected | triple-negative breast carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07137039 | Aug 2025 → Aug 2027 expected | hypopharynx cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07035392 | Jun 2025 → Dec 2026 expected | non-small cell lung carcinoma | Zhangzhou Municipal Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06962267 | Apr 2025 → Aug 2027 expected | malignant pancreatic neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06927180 | Apr 2025 → May 2029 expected | female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06684327 | Nov 2024 → Dec 2026 expected | extramammary Paget disease, penile cancer, rhabdomyosarcoma, testicular cancer +1 | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06489197 | Nov 2024 → Oct 2026 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06636981 | Nov 2024 → Sep 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06576973 | Aug 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06508229 | Jul 2024 → May 2027 expected | esophageal squamous cell carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06391008 | Apr → Dec 2024 | — | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT06371586 | Mar 2024 → Mar 2027 expected | diffuse gastric cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06304350 | Feb 2024 → Feb 2026 overdue | esophageal squamous cell carcinoma | Tongji University | Recruiting | No outcome recorded |
| Phase 2 | NCT06081673 | Oct 2023 → Dec 2024 overdue | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT05996484 | Sep 2023 → Nov 2024 overdue | esophageal cancer | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06000917 | May 2023 → May 2025 overdue | breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT05862168 | May 2023 → Jun 2024 overdue | oral cavity squamous cell carcinoma | Weijia Fang, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05918328 | May 2023 → Dec 2025 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05833971 | May 2023 → Jun 2024 | esophageal squamous cell carcinoma | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| Phase 2 | NCT05880082 | Jan 2023 → Aug 2025 | esophageal squamous cell carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT05738317 | Dec 2022 → Jun 2023 | non-small cell lung carcinoma | Xiaorong Dong | Unknown | No outcome recorded |
| Phase 2 | NCT06006650 | Aug 2022 → Dec 2031 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05497739 | Jun 2022 → Jun 2024 | gastric cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT05429294 | Jun 2022 → May 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT05515315 | May 2022 → May 2025 overdue | — | Fuzhou General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04888403 | Dec 2021 → Jul 2022 | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 2 | NCT05168527 | Sep 2021 → Mar 2024 | malignant pancreatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05860335 | Jul 2021 → Jun 2025 | hypopharynx cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06015035 | Apr 2021 → Apr 2022 | — | Tang-Du Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04922450 | Jan 2021 → Jan 2023 | head and neck cancer, squamous cell carcinoma | Hunan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05174325 | Dec 2020 → Jun 2022 | esophageal squamous cell carcinoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT04666090 | Nov 2020 → Dec 2022 overdue | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04884906 | Nov 2020 → Nov 2022 | cervical cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04499118 | Aug 2020 → Aug 2021 | Her2-receptor negative breast cancer | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04027764 | May 2019 → May 2020 | biliary tract cancer | Dai, Guanghai | Unknown | No outcome recorded |
| Phase 2 | NCT03650738 | Sep 2018 → Dec 2019 | — | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05125055 | Oct 2021 → Sep 2024 overdue | oral cavity squamous cell carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07613567 | Sep 2026 → Aug 2032 expected | cervical carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07400536 | Apr 2026 → Jul 2028 expected | cervical carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 3 | NCT06561763 | Aug 2024 → Aug 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06485557 | Aug 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06258811 | Feb 2024 → Dec 2026 expected | oral cavity squamous cell carcinoma | Lai-ping Zhong | Recruiting | No outcome recorded |
| Phase 3 | NCT06278870 | Sep 2023 → Jun 2031 expected | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05610332 | Nov 2022 → Nov 2024 overdue | gastric cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06578299 | Aug 2024 → Mar 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06494514 | Apr 2024 → Apr 2027 expected | pancreatic exocrine neoplasm | Du Juan | Recruiting | No outcome recorded |
| — | NCT04284215 | Sep 2019 → Sep 2021 | — | Guizhou Medical University | Unknown | No outcome recorded |
| Comparator or background therapy42 trials | ||||||
| Phase 1 | NCT06969612 Background | May 2025 → May 2027 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07385001 Background | Jan 2026 → Jan 2027 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07457528 Background | Mar 2026 → Jun 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07256964 Comparator | Nov 2025 → Dec 2028 expected | triple-negative breast carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07312578 Background | Nov 2025 → Nov 2027 expected | esophageal squamous cell carcinoma | Peking University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06714708 Background | Nov 2024 → Dec 2026 expected | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06492915 Background | Aug 2024 → May 2026 overdue | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06705127 Background | Jul 2024 → Jul 2025 overdue | hormone receptor-positive breast cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06427057 Background | Jul 2024 → Dec 2025 overdue | urinary system neoplasm | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06424899 Background | May 2024 → May 2027 expected | non-small cell lung carcinoma | Zeng Jian | Recruiting | No outcome recorded |
| Phase 2 | NCT06767813 Background | Mar 2024 → Nov 2026 expected | pancreatic neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06281886 Background | Dec 2023 → Dec 2026 expected | esophageal squamous cell carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05988372 Background | Oct 2023 overdue | pancreatic exocrine neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05787613 Background | Jul 2023 → Feb 2026 overdue | non-small cell lung carcinoma | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05947201 Background | May 2023 → Mar 2024 | — | Weijia Fang, MD | Unknown | No outcome recorded |
| Phase 2 | NCT06586242 Background | Apr 2023 → Apr 2025 overdue | esophageal cancer | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05673577 Background | Mar 2023 → Jun 2025 | head and neck squamous cell carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05659251 Background | Dec 2022 → Oct 2024 overdue | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05214222 Background | Sep 2022 → Jun 2026 overdue | esophageal squamous cell carcinoma | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05448781 Background | Jul 2022 → Jul 2023 | non-small cell lung carcinoma | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05420324 Background | Jun 2022 → Mar 2024 | mucosal melanoma | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05182944 Background | Jan 2022 → Jan 2024 overdue | esophageal cancer | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 2 | NCT04846452 Background | Jun 2021 → May 2023 | non-small cell squamous lung carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04836728 Background | Mar 2021 → Apr 2024 overdue | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04828395 Background | Mar 2021 → Mar 2023 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04681911 Background | Sep 2020 → Sep 2023 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04326153 Background | Mar 2020 → Sep 2023 overdue | non-small cell lung carcinoma | The First Hospital of Jilin University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05002686 Background | Aug 2021 → Aug 2023 | gastric cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04290793 Comparator | Mar 2020 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07445295 Background | Mar 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06957886 Comparator | May 2025 → May 2027 expected | breast carcinoma by gene expression profile | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06704620 Background | Dec 2024 → Nov 2026 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06561607 Comparator | Aug 2024 → Jan 2027 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05999149 Background | Aug 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05244798 Background | Nov 2022 → Dec 2025 overdue | esophageal squamous cell carcinoma | Sichuan Cancer Hospital and Research Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04768075 Background | May 2021 → Mar 2026 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Completed | Mixed |
| Phase 4 | NCT07302841 Background | Jan 2026 → Jun 2027 expected | pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07093931 Background | Aug 2025 → Aug 2027 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT06603974 Background | Oct 2024 → Jul 2026 overdue | gastric cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05378334 Background | Jun 2022 → Sep 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05341141 Background | Jun 2022 → Aug 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 93 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | albumin paclitaxel | “AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel...” NCT05378334 ↗92“Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2,...” NCT05182944 ↗ “After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab...” NCT06304350 ↗ “Non-squamous NSCLC subjects will receive pemetrexed/albumin paclitaxel and platinum (cisplatin/carboplatin), and squamous NSCLC subjects will receive albumin paclitaxel and...” NCT06485557 ↗ “Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer...” NCT06278870 ↗ “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin:...” NCT05880082 ↗ “Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.” NCT05341141 ↗ “AK104 (10 mg/kg d1), in combination with cisplatin (20 mg/m2 on d1-3) and albumin paclitaxel (100mg/m2 on d1,d8), fluorouracil (600 mg/m2 on d1-5) Q3W, intravenously” NCT05947201 ↗ “Iparomlimab/Tuvonralimab 5mg/kg,D1,Q3W + albumin paclitaxel 90mg/m2, D1、8、15，Q3W+ Cisplatin 25mg/m2 or Carboplatin AUC = 1.5 , D1、8、15，Q3W” NCT07613567 ↗ “AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）” NCT06427057 ↗ |
| Known as | Albumin Taxol | “Drug: Albumin Taxol” NCT05610332 ↗ |
| Known as | Nab-PTX | “Albumin Paclitaxel，260mg/m2 IV every 3 weeks D1, 8(Q3W)，Other Name: Nab-PTX” NCT05833971 ↗ |
| Route | Intravenous | “albumin paclitaxel 260mg/m2 intravenous drip d1” NCT03650738 ↗ |